Source comparison
Tesamorelin Safety Comparison: How It Stacks Against Other Growth Hormone Modulators
Half-Life 26 minutes ~2 hours 2.5–4 hours Tesamorelin clears fastest. Adverse effects resolve quickly if dosing stops IGF-1 Elevation +89–181 ng/mL (within physiological range) +50–120 ng/mL (variable by dose) +200–400 ng/mL (often supraphysiological) Lower IG
This comparison does not assign a generated winner or score.
- Half-Life
- 26 minutes
- ~2 hours
- 2.5–4 hours
- Tesamorelin clears fastest. Adverse effects resolve quickly if dosing stops
- IGF-1 Elevation
- +89–181 ng/mL (within physiological range)
- +50–120 ng/mL (variable by dose)
- +200–400 ng/mL (often supraphysiological)
- Lower IGF-1 peaks reduce theoretical proliferative risk
- Injection Site Reactions
- 62% (mild, transient)
- 15–25% (dose-dependent)
- 10–18%
- Highest local reactivity with tesamorelin. But rarely leads to discontinuation
- Edema Incidence
- 6.2%
- 8–12%
- 15–20%
- Lowest fluid retention among GH-modulating agents
- Glucose Dysregulation
- +4.9 mg/dL fasting glucose (stable HbA1c)
- Minimal impact in non-diabetics
- +8–15 mg/dL (HbA1c elevation documented)
- Tesamorelin's glycemic impact is modest and non-progressive
- Trial Duration & Scale
- 26-week Phase III + 104-week extensions, 804 participants
- Mostly 8–12 week trials, smaller cohorts
- Decades of post-market data, thousands of patients
- Tesamorelin has robust mid-term data but lacks decades-long observational cohorts
- Professional Assessment
- Most extensively studied GHRH analog for metabolic applications; safety profile well-characterized in HIV lipodystrophy but extrapolation to healthy populations requires caution
- Limited long-term human data; safety profile appears favorable in short-term trials but lacks regulatory approval for any indication
- Gold-standard safety data from pediatric and adult GH deficiency populations; higher side effect burden reflects supraphysiological dosing